President Donald Trump signed a landmark Executive Order on April 18, 2026, titled “Accelerating Medical Treatments for Serious Mental Illness,” directing federal agencies to dramatically speed up research, review, and potential access to psychedelic compounds, with specific emphasis on ibogaine. The move represents a significant policy shift aimed at addressing treatment-resistant depression, PTSD, addiction, and other severe mental health conditions that have not responded to conventional therapies.
The order instructs the FDA to issue Commissioner’s National Priority Vouchers for psychedelic drugs that have received Breakthrough Therapy designation, potentially shortening approval timelines from years to months. It also directs the FDA and DEA to create pathways for eligible patients to access investigational psychedelics, including ibogaine compounds, under the Right to Try Act. Additionally, the administration is allocating $50 million through ARPA-H to support state-led research initiatives, building on efforts already underway in places like Texas.
Ibogaine, a psychoactive alkaloid derived from the Tabernanthe iboga shrub native to Central Africa, has shown promising results in preliminary studies for interrupting opioid addiction and alleviating symptoms of PTSD and depression. However, its Schedule I status has historically limited research in the United States. The Executive Order explicitly highlights ibogaine compounds and opens the door for the first U.S. clinical trials of its derivative, noribogaine hydrochloride, with the FDA clearing an early-phase study for DemeRx NB shortly after the order was issued.
Health and Human Services Secretary Robert F. Kennedy Jr. and FDA officials have emphasized the potential of these therapies for veterans and others struggling with the ongoing mental health crisis. The policy builds on growing evidence from international studies and domestic advocacy, including support from veterans’ groups and high-profile voices like podcaster Joe Rogan. By prioritizing safety-reviewed compounds and expanding access under controlled conditions, the administration aims to balance innovation with responsible oversight.
The Executive Order has generated widespread attention across the medical community. While supporters hail it as a bold step toward breakthrough treatments, experts caution that challenges remain, particularly around ibogaine’s known cardiac risks, which require careful monitoring in clinical settings. The FDA has already granted priority reviews to other psychedelics, including psilocybin for depression and methylone for PTSD, signaling a broader acceleration across the field.
This development comes at a critical time as mental health issues continue to strain healthcare systems nationwide. Proponents argue that fast-tracking responsible research could offer new hope to millions who have exhausted traditional options. The order encourages collaboration between federal agencies, states, researchers, and private developers while maintaining strict safety protocols.
As implementation begins, the coming months will be pivotal. Researchers anticipate expanded clinical trials, increased funding opportunities, and clearer regulatory guidance. For patients and families affected by severe, treatment-resistant conditions, the Executive Order brings renewed optimism that long-overlooked psychedelic therapies may soon move from the margins into mainstream medicine.
The Trump administration’s decisive action underscores a growing recognition that innovative approaches are needed to tackle America’s mental health emergency. With ibogaine and other psychedelics now on a faster track, the United States is poised to play a leading role in what could become one of the most transformative chapters in psychiatric treatment history.